We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Agilent, ASI Announce Agreement

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Agilent Technologies Inc. and Applied Spectral Imaging (ASI) have announced they have entered into an agreement to jointly market ASI’s most advanced GenASIs imaging platforms and Agilent’s fluorescence in situ hybridization (FISH) products and solutions, including its Dako Omnis instrument for automated FISH sample processing.

This agreement is expected to bring to pathology labs the components for a fully automated, end-to-end FISH workflow. “We are excited to work with ASI,” said Herman Verrelst, vice president and general manager of Agilent’s Genomics Solutions Division and Clinical Applications Division.

“Difficulty of fluorescence-based molecular analysis has always been a major pain point for our customers. We anticipate that Agilent’s broad portfolio of FISH reagents and instruments, and ASI’s industry-leading computer-aided imaging solutions, will address such critical customer needs and enable laboratories to have a standardized, efficient and high-quality FISH workflow.”
“ASI is proud to partner with Agilent, a global leader in diagnostics that shares our main objective to make patient care better,” said Limor Shiposh, chief executive officer of ASI. “This agreement will position both companies to support customers in all stages of workflows.”